AU2017313450B2 - Viral vaccines - Google Patents

Viral vaccines Download PDF

Info

Publication number
AU2017313450B2
AU2017313450B2 AU2017313450A AU2017313450A AU2017313450B2 AU 2017313450 B2 AU2017313450 B2 AU 2017313450B2 AU 2017313450 A AU2017313450 A AU 2017313450A AU 2017313450 A AU2017313450 A AU 2017313450A AU 2017313450 B2 AU2017313450 B2 AU 2017313450B2
Authority
AU
Australia
Prior art keywords
virus
composition
poxvirus
deletion
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017313450A
Other languages
English (en)
Other versions
AU2017313450A1 (en
Inventor
Paul Howley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEMENTIS Ltd
Original Assignee
Segmentis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903295A external-priority patent/AU2016903295A0/en
Application filed by Segmentis Ltd filed Critical Segmentis Ltd
Publication of AU2017313450A1 publication Critical patent/AU2017313450A1/en
Application granted granted Critical
Publication of AU2017313450B2 publication Critical patent/AU2017313450B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017313450A 2016-08-19 2017-08-18 Viral vaccines Active AU2017313450B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903295A AU2016903295A0 (en) 2016-08-19 Viral Vaccines
AU2016903295 2016-08-19
PCT/AU2017/050879 WO2018032057A1 (en) 2016-08-19 2017-08-18 Viral vaccines

Publications (2)

Publication Number Publication Date
AU2017313450A1 AU2017313450A1 (en) 2019-02-28
AU2017313450B2 true AU2017313450B2 (en) 2024-02-15

Family

ID=61195904

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017313450A Active AU2017313450B2 (en) 2016-08-19 2017-08-18 Viral vaccines

Country Status (18)

Country Link
US (2) US10905759B2 (enExample)
EP (2) EP4331676A3 (enExample)
JP (1) JP2019528271A (enExample)
KR (1) KR20190050787A (enExample)
CN (1) CN109862909A (enExample)
AR (1) AR110624A1 (enExample)
AU (1) AU2017313450B2 (enExample)
CA (2) CA3265584A1 (enExample)
CL (1) CL2019000405A1 (enExample)
IL (1) IL264893B (enExample)
MA (1) MA45994A (enExample)
MX (1) MX2019001919A (enExample)
MY (1) MY200887A (enExample)
NZ (1) NZ750578A (enExample)
SG (1) SG11201900814QA (enExample)
TW (1) TWI728173B (enExample)
WO (1) WO2018032057A1 (enExample)
ZA (1) ZA201900641B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020086423A1 (en) * 2018-10-22 2020-04-30 Icell Kealex Therapeutics Mutant vaccinia viruses and use thereof
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
CN112362877B (zh) * 2020-10-27 2024-04-12 江苏先声医学诊断有限公司 一种mbp重组蛋白以及其应用
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0758397B1 (en) * 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
CN1418951A (zh) * 2001-05-23 2003-05-21 广州绿健生物技术有限公司 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法
EP2253709B1 (en) * 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
AU2003258168B2 (en) * 2002-08-12 2009-10-29 Sillajen Biotherapeutics, Inc. Methods and compositions concerning poxviruses and cancer
KR20040015624A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물
CN1723285B (zh) * 2003-02-18 2013-01-02 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 重组的mva及其产生方法
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
EP1683870A1 (en) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US20120328649A1 (en) 2010-09-23 2012-12-27 Baxter Healthcare S.A. Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus
RU2709771C2 (ru) * 2013-03-15 2019-12-19 Симентис Лимитед Иммунная модуляция
US10544397B2 (en) * 2013-11-01 2020-01-28 Sementis Limited Viral vector manufacture
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARCIA-ARRIAZA, J. et al. "A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection." J Virol. 2014 Mar;88(6):3527-47. doi: 10.1128/JVI.03418-13. Epub 2014 Jan 8. *
GERHARD, A. et al. "The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses." Virology. 1998 May 10;244(2):365-96. Review. Erratum in: Virology. 2006 Jul 5;350(2):501-2. *
VAN DEN DOEL, P. et al. "Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virusprotects AG129 mice against lethal challenge." PLoS Negl Trop Dis. 2014 Sep 4;8(9):e3101. *

Also Published As

Publication number Publication date
RU2019107582A (ru) 2020-09-21
IL264893A (enExample) 2019-04-30
TWI728173B (zh) 2021-05-21
SG11201900814QA (en) 2019-03-28
EP4331676A3 (en) 2024-05-15
TW201809273A (zh) 2018-03-16
CL2019000405A1 (es) 2019-06-14
US20200009245A1 (en) 2020-01-09
US10905759B2 (en) 2021-02-02
JP2019528271A (ja) 2019-10-10
MX2019001919A (es) 2019-09-04
AU2017313450A1 (en) 2019-02-28
EP4331676A2 (en) 2024-03-06
EP3500280A1 (en) 2019-06-26
AR110624A1 (es) 2019-04-17
US20210113684A1 (en) 2021-04-22
CN109862909A (zh) 2019-06-07
RU2019107582A3 (enExample) 2021-03-31
CA3034282A1 (en) 2018-02-22
IL264893B (en) 2022-08-01
NZ750578A (en) 2023-05-26
WO2018032057A1 (en) 2018-02-22
EP3500280A4 (en) 2020-05-13
KR20190050787A (ko) 2019-05-13
MA45994A (fr) 2021-03-17
MY200887A (en) 2024-01-22
CA3265584A1 (en) 2025-03-14
ZA201900641B (en) 2025-10-29
BR112019003181A2 (pt) 2019-07-16

Similar Documents

Publication Publication Date Title
KR102357051B1 (ko) 신규 유전자 재조합 백시니아 바이러스
AU746402B2 (en) Vectors having enhanced expression, and methods of making and uses thereof
AU2013312198B2 (en) Fluorescence activated cell sorting (FACS) enrichment to generate plants
CN113215109B (zh) 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用
AU2017353868B2 (en) Synthetic chimeric poxviruses
KR20210132002A (ko) 변형된 오르토폭스 바이러스 벡터
KR20230113832A (ko) 키메라 폭스바이러스 조성물 및 이의 용도
KR102205348B1 (ko) 외인성 항원을 포함하는 인간 시토메갈로바이러스
KR20150043540A (ko) Fad3 성능 유전자좌 및 표적화 파단을 유도할 수 있는 상응하는 표적 부위 특이적 결합 단백질
KR20150046345A (ko) 유전자 표적화 및 형질 스태킹을 위한 조작된 트랜스진 통합 플랫폼 (etip)
CN112899290B (zh) 一种天然免疫抑制基因缺失的减毒非洲猪瘟病毒株及应用
CN111212659B (zh) Hpv疫苗
CN113151310B (zh) 非洲猪瘟基因缺失弱毒株的构建及其作为疫苗的应用
KR20220031028A (ko) 아프리카 돼지 열병 백신
CN116348135A (zh) 基于重组痘病毒的抗SARS-CoV-2病毒疫苗
CN112543806A (zh) 合成嵌合痘苗病毒
AU2017313450B2 (en) Viral vaccines
KR101234062B1 (ko) 림프구 내 유전자 도입용 재조합 바이러스 벡터
CN113025629A (zh) 一种基因缺失的减毒非洲猪瘟病毒株及应用
CN115397998A (zh) 由天然或合成dna产生的基于痘病毒的载体及其用途
KR20230136600A (ko) 안정적인 세포주에서 효율적인 성장을 가능하게 하는아프리카 돼지 열병 백신의 게놈 결실
CN110546252A (zh) 具有广泛基因组对称的mva相关的新型痘苗病毒载体
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
CN117999090A (zh) 鼠痘病毒用于癌症免疫治疗和疫苗的用途
HK40078138A (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)